Category: Joints and SLE classification
Two Sore Fingers, a Positive ANA, and a High ESR Are Not the SLE Classification
Quick answer
The 2019 SLE classification criteria need a positive ANA once as the entry, then at least 10 points. In validation, sensitivity was 96.1 percent and specificity 93.4 percent. A positive ANA, a high sedimentation rate, and a negative rheumatoid factor do not by themselves reach that threshold.
Symptoms that need the team the same day
These do not wait for another biopsy.
- Very foamy urine, or swelling of the face or legs
- Chest pain on breathing, or breathlessness
- Confusion, unclear speech, a crooked mouth, or sudden arm or leg weakness
- High fever with a marked drop in alertness
One member’s question
One member described two sore fingers, a doctor’s statement that the pattern fit SLE in the joints, a high ESR, a positive ANA, a negative rheumatoid factor, and a biopsy report of inflammation rather than a malignant tumor. This page answers why that set does not equal the 2019 classification. It is not anyone’s lab sheet.
1. The entry and the 10 points are different steps
A positive ANA is the 2019 entry. Classification needs domain points of at least 10.
The criteria count domains, not fingers from a post
The 2019 EULAR/ACR criteria (PMID 31383717) use a positive ANA at least once as an obligatory entry. Additive weighted criteria then sit in seven clinical domains: constitutional, haematological, neuropsychiatric, mucocutaneous, serosal, musculoskeletal, and renal. Three immunological domains cover antiphospholipid antibodies, complement proteins, and SLE-specific antibodies. Weights run from 2 to 10. People who accumulate at least 10 points are classified. The abstract does not state how many sore fingers earn the musculoskeletal points.
The sensitivity belongs to the validation cohort
Weights were refined in a derivation cohort of 1,001 people and checked in a validation cohort of 1,270. In validation, sensitivity was 96.1 percent and specificity 93.4 percent, compared with 82.8 percent sensitivity and 93.4 percent specificity for the 1997 ACR criteria, and 96.7 percent sensitivity and 83.7 percent specificity for the 2012 SLICC criteria. The abstract presents these as classification criteria and a foundation for research. The figures are not the chance that a person with two sore fingers has SLE.
2. ANA is the entry. The ESR is not a domain
A positive ANA opens the 2019 entry. A high ESR is not written as a domain in that abstract.
Passing the entry is not reaching 10 points
A person who has never had a positive ANA is not classified by these criteria. A person with a positive ANA has only the entry. The remaining domains belong to the clinician who examines the joints, skin, blood, urine, and the antibodies the criteria name. This page gives no ANA titer, because the abstract says only positive at least once.
A high ESR is nonspecific inflammation
The abstract does not place the ESR in the seven clinical domains or the three immunological domains. A high value does not add points on this page, and this page has no reference range. The team that ordered the test reads it with the symptoms.
Which symptoms need a clinician now?
Our Advisory team can help sort severity and offer personalized guidance. There is no joint-lupus score on this site. Another layer’s score does not read an ANA and does not decide that this is SLE. Foamy urine, swelling, chest pain, or confusion needs emergency care before any score.
3. A negative rheumatoid factor and an inflamed biopsy answer different questions
A negative rheumatoid factor does not confirm SLE. A specimen without a malignant tumor answers that specimen.
Rheumatoid factor is not in the 2019 criteria
The abstract does not use rheumatoid factor as a domain. A negative result does not mean this is not rheumatoid arthritis, and it does not mean this is SLE. Whether a joint is swollen or tender belongs to the clinician who examined it.
The biopsy answers that piece of tissue
A report of inflammation without a malignant tumor answers the specimen that was sent. It does not add SLE domain points, and it does not survey the rest of the body for cancer.
4. Extra antibodies and a urine test belong to the team
The immunological domains include SLE-specific antibodies and complement. The rheumatology team chooses the tests. A kidney biopsy is not the next step after two sore fingers.
This page does not open an order list
The abstract names domains. It does not name a panel to request, and it does not give a percent specificity for each antibody. The treating clinician chooses when to test SLE-specific antibodies or complement.
Foamy urine or swelling is not an immediate kidney biopsy
Foamy urine or swelling needs care the same day. The urine test belongs to that team. A kidney biopsy is used when the kidney team already sees a kidney problem. Two sore fingers are not that step.
5. Four results that get folded into one label
Each result answers a different question. None of the four equals 10 points.
This table separates results. It does not diagnose one person.
| Result | What it answers | What this page does not conclude |
|---|---|---|
| Positive ANA | The 2019 entry is met | It is not yet 10 points |
| High ESR | Inflammation that is not specific | Not a domain in the abstract, and no reference range is given here |
| Negative rheumatoid factor | That assay did not find rheumatoid factor | It does not confirm SLE and it does not clear rheumatoid arthritis |
| Biopsy: inflammation, not a malignant tumor | The specimen showed inflammation and no malignant tumor | It does not classify SLE and it does not survey the whole body for cancer |
Figures from the 2019 criteria, and the limit on using them for one person
| Item | Figure in the abstract | Limit |
|---|---|---|
| Entry | Positive ANA at least once | Entry is not classification |
| Threshold | At least 10 domain points. Item weights from 2 to 10. | The abstract does not score two fingers |
| Cohorts | Derivation 1,001 people. Validation 1,270 people. | Research cohorts, not one lab sheet |
| Sensitivity and specificity | 96.1 percent and 93.4 percent in validation | Compared with the investigators’ classification, not the chance for a person with two sore fingers |
What this page takes from the abstract
Reviewed by Asst. Prof. Dr. Norawit Raatpiboon. The 2019 criteria separate the entry from the points. A positive ANA at least once is the entry. Later domains include the musculoskeletal system, the kidney, SLE-specific antibodies, and complement. People who accumulate at least 10 points are classified. In 1,270 validation subjects, sensitivity was 96.1 percent and specificity 93.4 percent. The ESR and rheumatoid factor are not domains in that abstract, so this page does not add them as points.
Frequently asked questions
The six answers below come from the 2019 criteria. They do not read one person’s lab sheet.
Do two sore fingers, a positive ANA, a high ESR, and a negative rheumatoid factor equal SLE?
They do not equal the 2019 classification. Entry is a positive ANA at least once. Classification then needs at least 10 domain points. A positive ANA alone, the ESR, and the rheumatoid factor are not listed as domains in that abstract.
What does a positive ANA mean in the 2019 criteria?
It is the obligatory entry, required at least once. A person without a positive ANA is not classified by these criteria. Passing the entry is not the same as reaching 10 points.
Does a high ESR add classification points?
The 2019 abstract does not place the ESR in the clinical or immunological domains. A high value is a nonspecific sign of inflammation. The team that ordered the test interprets it with the symptoms.
Does a negative rheumatoid factor prove this is SLE and not rheumatoid arthritis?
Rheumatoid factor is not in the 2019 criteria abstract. A negative result does not confirm SLE and does not clear rheumatoid arthritis.
Does a biopsy that says inflammation and not cancer prove SLE?
That report answers the specimen that was sent: inflammation was seen, and a malignant tumor was not seen in that piece. It does not add SLE classification points, and it does not survey the whole body for cancer.
Should a kidney biopsy be the next step, and which symptoms need same-day care?
A kidney biopsy is not the next step for two sore fingers. Foamy urine, swelling, chest pain on breathing, breathlessness, confusion, or sudden arm or leg weakness needs the emergency department the same day.
Source
The figures on this page come from one abstract.
- 2019 EULAR/ACR classification criteria for systemic lupus erythematosus. PMID 31383717
Medical disclaimer
This page is general education. It does not read anyone’s labs or biopsy, and it is not an order to draw blood, biopsy a kidney, start a medicine, or stop one. The diagnosis belongs to the clinician who examined the joints and holds the full results. Red-flag symptoms need emergency care the same day.